24th March 2022 Content supplied by: Sino Biological US Inc.
Recombinant Antigens for 2022-2023 Influenza Vaccine Strains
Vaccination is the most effective way to prevent flu infection. Each year, several different flu strains are selected as vaccine candidates based on surveillance data of the recent isolates and the performance of the vaccines from the previous season. In recent decades, most influenza vaccines are trivalent or quadrivalent, composed of one H1N1, one H3N2, and either one or two type B viruses (Yamagata and Victoria lineage).
Sino Biological offers recombinant ﬂu antigen products under its ProVir™ viral antigen collection. The product line covers Hemagglutinin (HA), Neuraminidase (NA), and Nucleoprotein (NP) proteins from all WHO-recommended vaccine strains in recent years. These antigens can be used to analyze vaccine-induced antibody response.
In addition, Sino Biological also develops a large collection of monoclonal antibodies against the ﬂu antigens. These reagents can help facilitate relevant assay development.
Visit Sino Biological or click on the Request Information button below.
Date Published: 24th March 2022
Source article link: View
Sino Biological Invests Over 200M
Sino Biological and Ainnocence Partner